This site is intended for health professionals only!

Abbott Labs in £300m Facet buyout

teaser

Pharmaceutical company Abbott Laboratories has reached a deal to buy Facet Biotech for an estimated £300 million, it has been announced.

The acquisition will see Abbott venture further into the biotechnology treatment field, as well as adding a potential multiple sclerosis drug to its treatment stable.

Facet and partner Biogen Idec had hoped to move the potential treatment, daclizumab, into late-stage development within the next few months. The company also has a potential cancer treatment in development.

Abbott, based in Chicago, Illinois, valued the deal at a total of £483 million, a price that came down once Facet’s marketable securities and projected cash were deducted.

The buy-out will not affect the company’s profit expectations for 2010, although a one-off sum will undoubtedly be charged.

Facet, based in California, was advised by Centerview Partners throughout negotiations.

Copyright Press Association 2010
Abbott Laboratories
Facet Biotech



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: